LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Cerrado

3.25 5.86

Resumen

Variación precio

24h

Actual

Mínimo

3.02

Máximo

3.2800000000000002

Métricas clave

By Trading Economics

Ingresos

-17M

-70M

Ventas

547K

47M

Margen de beneficio

-147.345

Empleados

560

EBITDA

-17M

-66M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+50.87% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

324M

1.1B

Apertura anterior

-2.61

Cierre anterior

3.25

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 nov 2025, 23:59 UTC

Ganancias

Singtel's 1st Half Net Profit Surges

11 nov 2025, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11 nov 2025, 22:21 UTC

Ganancias

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11 nov 2025, 23:52 UTC

Charlas de Mercado

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11 nov 2025, 23:44 UTC

Ganancias

Singtel's 1H Net Profit Surges

11 nov 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11 nov 2025, 23:18 UTC

Ganancias

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11 nov 2025, 23:15 UTC

Ganancias

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11 nov 2025, 23:14 UTC

Ganancias

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11 nov 2025, 23:12 UTC

Ganancias

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11 nov 2025, 23:11 UTC

Ganancias

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11 nov 2025, 23:10 UTC

Ganancias

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11 nov 2025, 23:04 UTC

Charlas de Mercado

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11 nov 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

11 nov 2025, 21:50 UTC

Charlas de Mercado
Ganancias

Health Care Roundup: Market Talk

11 nov 2025, 21:46 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11 nov 2025, 21:41 UTC

Ganancias

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11 nov 2025, 21:40 UTC

Ganancias

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11 nov 2025, 21:39 UTC

Ganancias

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11 nov 2025, 21:39 UTC

Ganancias

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11 nov 2025, 21:39 UTC

Ganancias

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11 nov 2025, 21:38 UTC

Ganancias

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11 nov 2025, 21:38 UTC

Ganancias

Aristocrat: Final Dividend 49 Australian Cents/Share

11 nov 2025, 21:37 UTC

Ganancias

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11 nov 2025, 21:36 UTC

Ganancias

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11 nov 2025, 21:35 UTC

Ganancias

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11 nov 2025, 21:35 UTC

Ganancias

Alcon 3Q Adj EPS 79c >ALC

11 nov 2025, 21:35 UTC

Ganancias

Alcon 3Q Rev $2.61B >ALC.EB

11 nov 2025, 21:35 UTC

Ganancias

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11 nov 2025, 21:35 UTC

Ganancias

Alcon 3Q EPS 48c >ALC.EB

Comparación entre iguales

Cambio de precio

Maravai LifeSciences Holdings Inc (Class A) Esperado

Precio Objetivo

By TipRanks

50.87% repunte

Estimación a 12 meses

Media 4.33 USD  50.87%

Máximo 5 USD

Mínimo 4 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Maravai LifeSciences Holdings Inc (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

4

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.02 / 2.115Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat